tiprankstipranks
Trending News
More News >
Rein Therapeutics (RNTX)
NASDAQ:RNTX
Advertisement

Rein Therapeutics (RNTX) Stock Statistics & Valuation Metrics

Compare
1,194 Followers

Total Valuation

Rein Therapeutics has a market cap or net worth of $29.60M. The enterprise value is $73.15M.
Market Cap$29.60M
Enterprise Value$73.15M

Share Statistics

Rein Therapeutics has 23,305,107 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,305,107
Owned by Insiders2.08%
Owned by Institutions0.61%

Financial Efficiency

Rein Therapeutics’s return on equity (ROE) is -1.16 and return on invested capital (ROIC) is -112.59%.
Return on Equity (ROE)-1.16
Return on Assets (ROA)-1.01
Return on Invested Capital (ROIC)-112.59%
Return on Capital Employed (ROCE)-1.15
Revenue Per Employee0.00
Profits Per Employee-5.72M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Rein Therapeutics is ―. Rein Therapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value<0.01
Price to FCF
Price to Operating Cash Flow-1.25
PEG Ratio

Income Statement

In the last 12 months, Rein Therapeutics had revenue of 0.00 and earned -62.88M in profits. Earnings per share was -3.51.
Revenue0.00
Gross Profit-63.00K
Operating Income-65.11M
Pretax Income-64.31M
Net Income-62.88M
EBITDA-28.05M
Earnings Per Share (EPS)-3.51

Cash Flow

In the last 12 months, operating cash flow was -21.22M and capital expenditures 0.00, giving a free cash flow of -21.22M billion.
Operating Cash Flow-21.22M
Free Cash Flow-21.22M
Free Cash Flow per Share-0.91

Dividends & Yields

Rein Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.99
52-Week Price Change-48.16%
50-Day Moving Average1.39
200-Day Moving Average1.97
Relative Strength Index (RSI)51.36
Average Volume (3m)59.59K

Important Dates

Rein Therapeutics upcoming earnings date is Nov 14, 2025, TBA (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateNov 14, 2025
Ex-Dividend Date

Financial Position

Rein Therapeutics as a current ratio of 2.38, with Debt / Equity ratio of 0.00%
Current Ratio2.38
Quick Ratio2.38
Debt to Market Cap0.00
Net Debt to EBITDA0.46
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Rein Therapeutics has paid -1.54M in taxes.
Income Tax-1.54M
Effective Tax Rate0.02

Enterprise Valuation

Rein Therapeutics EV to EBITDA ratio is 0.46, with an EV/FCF ratio of 0.58.
EV to Sales0.00
EV to EBITDA0.46
EV to Free Cash Flow0.58
EV to Operating Cash Flow0.58

Balance Sheet

Rein Therapeutics has $5.72M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$5.72M billion.
Cash & Marketable Securities$5.72M
Total Debt$0.00
Net Cash-$5.72M
Net Cash Per Share-$0.25
Tangible Book Value Per Share$326.79

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Rein Therapeutics is $8.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$8.00
Price Target Upside529.92% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast
EPS Growth Forecast17.02%

Scores

Smart Score4
AI Score38
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis